VNVALUEVNVALUE
Updated weekly
Back to Dashboard
Consumer sector

PMC

Consumer
Công ty Cổ phần Dược phẩm Dược liệu Pharmedic
Y tế/Dược phẩmCT
126.000
VND · Last close
Valuation Verdict
Overvalued
Low
-120%Fair Value+120%
Intrinsic Value
95.241
Current
126.000
Gap
-24.4%
ModelFCF DCF

Valuation Breakdown

CTY tếConsumer
Classified as consumer because ICB sector "Y tế" maps to the consumer group
ModelFCF-Based DCF
Value = Sum of [FCF / (1+WACC)^t] + Terminal Value / (1+WACC)^n

A classic Discounted Cash Flow model built on Free Cash Flow (FCF), the actual cash a business generates after all operating expenses and capital expenditures. Future FCF is projected for 10 years with gradually decaying growth, then discounted back to today's value using WACC. This is the gold standard of intrinsic valuation: it values the company based on what it can actually deliver to shareholders, independent of market sentiment.

1
Weighted Avg Cost of Capital
Risk-Free (Rf)
4.50%
+
Betasector default
0.800
x
ERP
4.25%
+
CRP
2.75%
=
Cost of Equity (Ke)
10.10%
Ke
10.10%
x
E/(D+E)
77.06%
+
Kd(1-t)
6.39%
x
D/(D+E)
22.94%
=
WACC
10.00%
2
Growth Estimate
fundamental firm blend10.20%
Growth decays 10%/yr toward terminal
3
Model Inputs
Base FCF39.23B
Projection years10
4
Valuation
Base FCF
39.23B
Growth Rate
10.20%
WACC
10.00%
Terminal Growth
4.00%
DCF Value
95.241
Value Decomposition
41%
59%
Explicit period (41%)Terminal value (59%)

Valuation Track Record

Retroactive intrinsic value vs actual close price — PMC

Earnings Quality

Fiscal year 2025

53
Fair
Accrual Quality
37
Cash Conversion
18
Receivables
100
Margin Stability
100
Revenue Quality
29

Financial Forensics

Beneish M-Score · 2025

0.33
High Risk
DSRI
0.961
GMI
0.920
AQI
5.792
SGI
1.097
DEPI
2.192
SGAI
1.181
TATA
0.185
LVGI
1.319

The Beneish M-Score of 0.331 indicates a potential risk of earnings manipulation, as it is above the threshold of -1.78. Additionally, the earnings quality metrics show weaknesses in cash conversion and revenue recognition, which could raise concerns for investors.

Red Flags
  • Beneish M-Score of 0.331 suggests potential earnings manipulation, as it exceeds the threshold of -1.78.
  • Earnings Quality Score of 53.1/100 reflects low cash conversion (18.0/100) and revenue recognition (28.6/100), indicating potential issues in financial reporting.
Positive Signals
  • Strong receivables (100.0/100) and margin (100.0/100) scores indicate effective management of these areas, which could support revenue stability.
Ownership Risk

The ownership structure is heavily concentrated, with the top two institutions holding 43.4% each, which may lead to conflicts of interest and reduced minority shareholder influence.

Recommendation

Investors should conduct further due diligence on PMC's financial practices and consider monitoring future earnings reports closely for signs of improvement in cash conversion and revenue recognition.

Generated by AI based on quantitative data. Not financial advice.

Quantitative Scores

F-Score
6/9
Neutral
Z-Score
12.01
Safe Zone
Sharpe
0.63
Positive
Composite
56
Fair
Price Risk
Momentum
+54.1%
Volatility
71.7%
Max Drawdown
-29.1%

Key Ratios

Fiscal year 2025
15.50P/E
P/B5.30
P/S2.33
ROE31.0%
ROA22.8%
EPS8819.10
BVPS25808.03
Gross Margin40.8%
Net Margin15.1%
D/E0.43
Current Ratio2.10
Rev Growth9.9%
Profit Growth2.7%
EV/EBITDA11.24
Div Yield0.7%

Company Overview

Issued Shares
9.3M
Charter Capital
93.3B VND
Sector (ICB L2)
Y tế
Industry (ICB L3)
Dược phẩm
Sub-industry
Dược phẩm
Company Type
CT

// OWNERSHIP_NETWORK

> mapping common ownership for PMC — hover nodes for intel, click to navigate

Shareholders
Công ty TNHH Dược Phẩm Sài Gòn
Inst
43.4%
4.1 trieu
Công ty TNHH MTV Dược Sài Gòn
Inst
43.4%
4.1 trieu
Quỹ Đầu Tư Hạ Tầng PVI
Inst
21.6%
2.0 trieu
CÔNG TY CỔ PHẦN ĐẦU TƯ VÀ KINH DOANH DƯỢC PHẨM VIỆT NAM
Inst
15.9%
1.5 trieu
Trần Văn Nhiều
Indiv
0.7%
60.948
Mai Thị Bé
Indiv
0.3%
23.947
Ngô Minh Trí
Indiv
0.3%
23.420
Phan Xuân Phong
Indiv
0.2%
23.186
Lâm Bình Lễ
Indiv
0.2%
22.576
Nguyễn Văn Kính
Indiv
0.2%
21.074
Trà Quang Trinh
Indiv
0.2%
20.300
nguyen-huu-duc
Indiv
0.2%
19.317
Cao Tấn Tước
Indiv
0.2%
18.364
Trần Thị Thu Trang
Indiv
0.2%
16.339
Phan Minh Tịnh
Indiv
0.1%
12.266
Đặng Văn Giáp
Indiv
0.1%
11.540
Trần Thị Thu Trang
Indiv
0.1%
11.285
Nguyễn Thị Thúy Vân
Indiv
0.1%
10.019
Board & Management
Phan Xuân Phong0.2%
Phó Tổng Giám đốc
Trà Quang Trinh0.2%
Phó Tổng Giám đốc
Nguyễn Thị Kim Tuyến
Thành viên Hội đồng Quản trị/Phó Tổng Giám đốc Tổ chức hành chính
Trần Việt Trung
Thành viên Hội đồng Quản trị/Tổng Giám đốc
Phạm Thị Hoàng
Trưởng Ban kiểm soát
Trần Đình Thủy
Trưởng phòng Tài chính - Kế toán/Kế toán trưởng/Giám đốc Tài chính
Nguyễn Huy Cường
Thành viên Hội đồng Quản trị
Lê Việt Hùng
Chủ tịch Hội đồng Quản trị
Bùi Thụy Phương Uyên
Người phụ trách quản trị công ty/Phụ trách Công bố thông tin
Nguyễn Quý Thịnh
Thành viên Hội đồng Quản trị
Trần Đức Thắng
Thành viên Hội đồng Quản trị
Lê Hữu Hùng
Thành viên Ban kiểm soát
Nguyễn Thế Phong
Thành viên Ban kiểm soát
Computed 12/04/2026
Methodology & Disclosure

vnvalue is a methodology engine — not an advisor. Every number is the deterministic output of a published formula applied to public financial data. Nothing on this page constitutes investment, financial, legal, or tax advice, nor a recommendation to buy, sell, or hold any security.

All data, models, and outputs are provided AS IS without warranty of any kind. You are solely responsible for your investment decisions. Past performance and historical valuations are not indicative of future results.

By using vnvalue you accept the Terms of Service and Privacy Policy. Full disclaimer →